Company Overview
CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development to treat cancer and other diseases by using the immune system in the United States. The company's lead immunotherapy is Multikine, which has completed Phase III clinical trials for the potential treatment of certain head and neck cancers. It is also developing Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer, as well as to potentially treat rheumatoid arthritis. In addition, the company's LEAP product candidates include CEL-2000; CEL-4000; and CEL-5000 that are in preclinical trials for potential rheumatoid arthritis therapeutic treatments. CEL-SCI Corporation has a strategic partnership with Saudi Arabian Pharma Company for Multikine in the treatment of head and neck cancer. The company was incorporated in 1983 and is headquartered in Vienna, Virginia.
Recent Developments
- Trailing 12 Months Year-on-year growth — revenue +65.5%.
- 5-Year Trend Long-term compounding — revenue CAGR -34.9%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -34.88% |
| 1 Year: | 65.45% |
Stock Price Performance
| 1 Year: | -80.24% |
| 6 Months: | -57.36% |
| 3 Months: | +19.57% |
| 1 Month: | -4.07% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMABelow
- RSI (14)59.49 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Revenue declined at -34.9% CAGR over 5 years.
- Trading 87.3% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | CVM CEL-SCI Corporation PHARMA | 1.65 | -0.98 | $29.02M | 0.00% | -107.75% | - | -34.88% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2013 | Mar 2014 | Jun 2014 | Sep 2014 | Dec 2014 | Mar 2015 | Jun 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 113.14K | 67.16K | 15.91K | 67.82K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Income | -5.93M | -6.23M | -6.90M | - | -10.00M | -7.76M | -8.20M | - | -5.78M | -6.27M | -6.38M | -4.94M | -7.91M | -4.76M | -4.93M | -4.22M | -4.09M | -5.03M | -4.31M | -5.21M | -6.86M | -6.72M | -6.97M | -8.73M | -8.53M | -10.46M | -8.84M | -9.55M | -8.72M | -7.65M | -8.18M | -8.18M | -6.49M | -7.08M | -6.67M | -6.89M | -6.39M | -5.49M | -5.37M | -5.33M |
| Net Income | -4.33M | -13.37M | -2.44M | -7.22M | -7.85M | -12.56M | -4.43M | - | 2.34M | -8.84M | -3.85M | 3.52M | -8.43M | -4.46M | -6.19M | -4.71M | -6.01M | 1.25M | -6.45M | -12.08M | -5.53M | -9.07M | -10.28M | -7.94M | -11.28M | -8.94M | -8.78M | -9.82M | -9.63M | -7.85M | -8.34M | -8.37M | -6.71M | -7.24M | -6.86M | -7.07M | -6.57M | -5.66M | -5.47M | -5.47M |
| Diluted EPS | -0.15 | -0.24 | -0.11 | -0.13 | -0.14 | -0.17 | -0.06 | -0.10 | 0.02 | - | -0.03 | 0.32 | -1.15 | -0.53 | -0.53 | -0.31 | -0.36 | 0.02 | -0.22 | - | -0.16 | -0.25 | -0.27 | -0.21 | -0.28 | -0.25 | -0.20 | -0.23 | -0.23 | -0.18 | - | - | -0.14 | -0.14 | -4.18 | -3.25 | -2.33 | -1.36 | -0.68 | -0.67 |
| R&D Expense | 4.02M | 4.15M | 4.45M | - | 4.85M | 5.08M | 5.73M | - | 5.17M | 4.63M | 4.84M | 3.55M | 6.58M | 3.18M | 2.33M | 2.96M | 2.43M | 3.47M | 2.83M | 2.30M | 4.25M | 4.46M | 3.97M | 5.41M | 5.22M | 7.18M | 6.08M | 6.52M | 6.29M | 5.39M | 6.08M | 5.73M | 4.35M | 4.63M | 4.70M | 4.43M | 4.01M | 3.74M | 3.68M | 3.77M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Sep 2009 | Sep 2010 | Sep 2011 | Sep 2012 | Sep 2013 | Sep 2014 | Sep 2015 | Sep 2016 | Sep 2017 | Sep 2018 | Sep 2019 | Sep 2020 | Sep 2021 | Sep 2022 | Sep 2023 | Sep 2024 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | 956.15K | 254.61K | 159.58K | 264.03K | - | - | - | - | - | - | - | - | - | - | - |
| Operating Income | -12.02M | -18.56M | -17.99M | -17.24M | -19.87M | -27.57M | -34.30M | -23.65M | -21.41M | -16.77M | -20.20M | -28.99M | -36.19M | -36.06M | -31.48M | -26.35M | -24.81M |
| Net Income | -40.91M | 10.48M | -25.71M | -15.48M | -9.17M | -27.37M | -34.67M | -11.51M | -14.36M | -31.84M | -22.13M | -30.26M | -36.36M | -36.70M | -32.37M | -26.92M | -25.41M |
| Diluted EPS | -0.31 | -0.06 | -1.49 | -0.78 | -0.66 | -0.49 | -0.42 | -2.37 | -1.91 | -1.87 | -0.71 | -0.82 | -0.90 | -0.87 | -0.73 | -15.31 | -6.27 |
| R&D Expense | 6.01M | 11.91M | 11.75M | 10.37M | 12.68M | 17.17M | 21.10M | 17.45M | 15.61M | 10.91M | 12.66M | 17.84M | 23.11M | 25.36M | 22.47M | 18.16M | 15.89M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Sep 2008 | Sep 2009 | Sep 2010 | Sep 2011 | Sep 2012 | Sep 2013 | Sep 2014 | Sep 2015 | Sep 2016 | Sep 2017 | Sep 2018 | Sep 2019 | Sep 2020 | Sep 2021 | Sep 2022 | Sep 2023 | Sep 2024 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 37.80M | 18.63M | 16.07M | 10.84M | 19.23M | 15.45M | 24.89M | 22.92M | 29.59M | 27.62M | 40.54M | 75.87M | 50.52M | 30.53M | 26.99M | 28.16M |
| Total Equity | 10.84M | 8.84M | 27.85M | 9.08M | 7.03M | 6.70M | 10.44M | -4.76M | -679.21K | -3.34M | 916 | 5.13M | 19.73M | 56.53M | 32.16M | 13.21M | 12.87M | 15.96M |
| Cash & Equivalents | 711.26K | 33.57M | 26.57M | 4.26M | 3.94M | 41.61K | 8.51M | 5.73M | 2.92M | 2.37M | 10.31M | 8.44M | 15.51M | 36.06M | 22.67M | - | - | - |
| Total Liabilities | - | - | 9.95M | 9.55M | 9.04M | 4.14M | 8.79M | 20.53M | 25.57M | 26.26M | 29.59M | 22.49M | 20.81M | 19.34M | 18.36M | 17.31M | 14.12M | 12.20M |
| Current Liabilities | - | - | 3.30M | 7.22M | 1.91M | 3.55M | 3.15M | 6.71M | 4.01M | 10.84M | 9.23M | 3.02M | 4.27M | 3.94M | 4.66M | 5.59M | 4.62M | 5.13M |
Cash Flows (Annual)
Figures in USD.
| Metric | Sep 2009 | Sep 2010 | Sep 2011 | Sep 2012 | Sep 2013 | Sep 2014 | Sep 2015 | Sep 2016 | Sep 2017 | Sep 2018 | Sep 2019 | Sep 2020 | Sep 2021 | Sep 2022 | Sep 2023 | Sep 2024 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -6.51M | -12.80M | -22.56M | -12.19M | -13.55M | -22.93M | -23.83M | -23.08M | -13.79M | -13.39M | -16.32M | -15.28M | -18.79M | -18.24M | -22.85M | -18.81M | -17.12M |
| Investing Cash Flow | 368.72K | -503.94K | -318.11K | -133.60K | -132.76K | -138.86K | -93.53K | -34.22K | -17.00K | -58.14K | -335.84K | -2.69M | -15.18M | 5.49M | -372.26K | -108.09K | -38.11K |
| Financing Cash Flow | 39.00M | 6.31M | 565.87K | 12.00M | 9.78M | 31.54M | 21.14M | 20.31M | 13.26M | 21.39M | 14.79M | 25.04M | 54.52M | -638.43K | 4.69M | 19.51M | 23.37M |
| Capital Expenditure | 191.87K | -493.74K | -216.76K | -54.64K | -102.03K | -103.98K | -73.40K | -31.41K | -10.53K | -1.01K | 177.78K | -2.65M | -9.02M | -637.89K | -361.89K | -94.88K | -38.11K |
| Free Cash Flow | -6.32M | -13.30M | -22.77M | -12.24M | -13.65M | -23.03M | -23.91M | -23.11M | -13.80M | -13.39M | -16.14M | -17.93M | -27.80M | -18.88M | -23.21M | -18.91M | -17.16M |
Ratios (Annual)
Figures in %.
| Metric | Sep 2009 | Sep 2010 | Sep 2011 | Sep 2012 | Sep 2013 | Sep 2014 | Sep 2015 | Sep 2016 | Sep 2017 | Sep 2018 | Sep 2019 | Sep 2020 | Sep 2021 | Sep 2022 | Sep 2023 | Sep 2024 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | -1,881.0% | -6,772.3% | -12,450.1% | -10,443.4% | - | - | - | - | - | - | - | - | - | - | - |
| Net Margin % | - | - | -2,689.1% | -6,078.8% | -5,746.8% | -10,364.7% | - | - | - | - | - | - | - | - | - | - | - |
| ROE % | -462.7% | 37.6% | -283.2% | -220.2% | -136.9% | -262.0% | 728.1% | 1,695.0% | 430.4% | -3,475,677.4% | -431.2% | -153.4% | -64.3% | -114.1% | -244.9% | -209.2% | -159.2% |
| ROCE % | - | -53.8% | -157.8% | -121.8% | -272.4% | -171.5% | -392.3% | -113.3% | -177.2% | -82.4% | -82.1% | -79.9% | -50.3% | -78.6% | -126.2% | -117.8% | -107.8% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Renaissance Technologies, LLC | 3.28% | 572.46K | $950.28K |
| 2 | Vanguard Capital Management LLC | 3.11% | 543.08K | $901.51K |
| 3 | Citadel Advisors Llc | 1.14% | 198.50K | $329.51K |
| 4 | MAI Capital Management | 0.62% | 108.28K | $179.74K |
| 5 | Geode Capital Management, LLC | 0.50% | 88.20K | $146.41K |
| 6 | Commonwealth Equity Services, LLC | 0.29% | 51.43K | $85.38K |
| 7 | HRT Financial LP | 0.29% | 51.16K | $84.92K |
| 8 | Vanguard Fiduciary Trust Co | 0.28% | 49.04K | $81.40K |
| 9 | Blackrock Inc. | 0.25% | 43.26K | $71.81K |
| 10 | Bank of America Corporation | 0.23% | 40.92K | $67.92K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for CVM
CVM Stock Sinks In Pre-Market Trading After Announcing Second Equity Raise For Its Cancer Drug In Just Over A Month - Stocktwits
<a href="https://news.google.com/rss/articles/CBMiqAFBVV95cUxQdm5ldXNSMEZRQ2NTQWVNd1lMVHpHaExiRV9jMlctVDJHZjBzbXhnUmlOSXF3aGFBRjBEQnl5NE5yVlItY05OYzNKQTlZY3BnU2dDSkVBeTlUTTdpXzY3czZNbVhkOGNidE9WZENkcnl3b3ZCMjFKSWJqWDF1b2pCUG9OSVE1UnZxRC0xaE…
73% Five-Year Survival: Which Patients Will CEL-SCI Study Next? - Stock Titan
<a href="https://news.google.com/rss/articles/CBMimwFBVV95cUxQb3N6WFlpaEE1RlhsZGdEcFNfNWJwU2MtQWNTcHpOczgxVnFNaGRmR2dBTnZhaS1HN01iemJzSm55QWtVUW5kVUZVcGx2dmNOWHZLYnZneEU4VkJoY2dQOUIybUZ5R1lwcHlTX0c4a0RxbWFPclo3N1YtQ0xWdjlNaDJEQ1lBeFk2VUpPRz…
$CVM stock is up 17% today. Here's what we see in our data. - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMinwFBVV95cUxNOG5DcDA2T1FKZDl4ZVNSWGk2RVBaTUZvRlZEc1Y5bHdsbG0xVjdtSEZkQmN4c0hpRENpTld1R2pFRUt5Z25uNU43d0IwbGlUOW05bWEybFk3MU9sZHhwZUFZVGRYUFdEaXhIWFRHaVJqZG51MVdpcjQ0cEJnQzVoaXdwWVFZNHp0RmZWRV…
Cel-Sci Corporation (CVM) Stock Analysis: Exploring the Potential of a Biotech Challenger with a Unique Immunotherapy Approach - directorstalkinterviews.com
<a href="https://news.google.com/rss/articles/CBMihAJBVV95cUxOUjhHTDl2RTFlamVFc0daTXcxSFoxZVItYl9oaUtYMmczZG85bGx0XzFZSGgzUklTMFN0d1Y4OUJSaTNiNTdtb1BMeFJqSlRKMGstWjVBRW9waTdyWGR6cVIzQTZEUlVoczJ5UmFwZDlUNU8ta2JrdndQa0c1dlNQX3hUTFdIR1luVzZUQm…
CVM - Finviz
<a href="https://news.google.com/rss/articles/CBMiREFVX3lxTFBHYXFrZzJwOUh0U09HXzZBQXAwWW5seEhUa3BzbDM0MTQ4ZEl4NUh0bHVSX2p5MjJON2dKeExSLUhUX1Zt?oc=5" target="_blank">CVM</a> <font color="#6f6f6f">Finviz</font>…
CVM|CEL-SCI Corp|Price:1.650|Chg%:+0.040 - TradingKey
<a href="https://news.google.com/rss/articles/CBMibEFVX3lxTE80QXZFU1pFaS1LeW9Ob3dWLWphUkRGTXpTS2RaVnJwWnZvQU9WTE9KbTN0N0Q4YlJ5X09yaVhkQ3RoUGRfYkFLU3VrcEUyT3NoUzhWcnlpUFRmYWdFSVZBcFdtaWJXYkdlQ3lGNQ?oc=5" target="_blank">CVM|CEL-SCI Corp|Pric…
CVM — Frequently Asked Questions
What is the current share price of CEL-SCI Corporation (CVM)?
As of 2026-09-19 21:16 PDT, CEL-SCI Corporation (CVM) trades at $1.65 on NYSE American. Its 52-week range is $0.97 to $13.04.
What is the market capitalisation of CVM?
CEL-SCI Corporation (CVM) has a market capitalisation of $29.02M on NYSE American.
What is the P/E ratio of CVM?
CVM trades at a trailing price-to-earnings (P/E) ratio of -0.98. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 2.47.
Is CVM a good stock to buy?
This page provides a data-driven analysis of CEL-SCI Corporation (CVM), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.